Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2020

Open Access 01-04-2020 | Endoscopy | Original Article

Increased prevalence of Barrett’s esophagus in patients with MUTYH-associated polyposis (MAP)

Authors: Ceranza G. Daans, Zeinab Ghorbanoghli, Mary E. Velthuizen, Hans F. A. Vasen, George J. A. Offerhaus, Miangela M. Lacle, Peter D. Siersema, Margreet G. E. M. Ausems, Jurjen J. Boonstra

Published in: Familial Cancer | Issue 2/2020

Login to get access

Abstract

Barrett’s oesophagus (BE) has been associated with an increased risk of both colorectal adenomas and colorectal cancer. A recent investigation reported a high frequency of BE in patients with adenomatous polyposis coli (APC)-associated polyposis (FAP). The aim of the present study is to evaluate the prevalence of BE in a large cohort of patients with MUTYH-associated polyposis (MAP) and APC-associated adenomatous polyposis. Patients with a genetically confirmed diagnosis of familial adenomatous polyposis (FAP) or MAP were selected and upper gastrointestinal (GI) endoscopy reports, pathology reports of upper GI biopsies were reviewed to determine the prevalence of BE in these patients. Histologically confirmed BE was found in 7 (9.7%) of 72 patients with MAP. The mean age of diagnosis was 60.2 years (range 54.1–72.4 years). Two patients initially diagnosed with low grade dysplasia showed fast progression into high grade dysplasia and esophageal cancer, respectively. Only 4 (1.4%) of 365 patients with FAP were found to have pathologically confirmed BE. The prevalence of BE in patients with MAP is much higher than reported in the general population. We recommend that upper GI surveillance of patients with MAP should not only focus on the detection of gastric and duodenal adenomas but also on the presence of BE.
Literature
1.
Hvid-Jensen F, Pedersen L, Drewes AM et al (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383CrossRef
2.
Harrison RF, Perry I, Balkwill F et al (2000) Barrett’s metaplasia. Lancet 356:2079–2085CrossRef
3.
Levine DM, Ek WE, Zhang R et al (2013) A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet 45:1487–1493CrossRef
4.
Ek WE, Levine DM, D’Amato M et al (2013) Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett’s esophagus, and gastroesophageal reflux. J Natl Cancer Inst 105:1711–1718CrossRef
5.
Ronkainen J, Aro P, Storskrubb T et al (2005) Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 129:1825–1831CrossRef
6.
Zagari RM, Fuccio L, Wallander MA et al (2008) Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut 57:1354–1359CrossRef
7.
Peng S, Cui Y, Xiao YL et al (2009) Prevalence of erosive esophagitis and Barrett’s esophagus in the adult Chinese population. Endoscopy 41:1011–1017CrossRef
8.
Lee IS, Choi SC, Shim KN et al (2010) Prevalence of Barrett’s esophagus remains low in the Korean population: nationwide cross-sectional prospective multicenter study. Dig Dis Sci 55:1932–1939CrossRef
9.
Zou D, He J, Ma X et al (2011) Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol 46:133–141CrossRef
10.
Kumaravel A, Thota PN, Lee HJ et al (2014) Higher prevalence of colon polyps in patients with Barrett’s esophagus: a case–control study. Gastroenterol Rep (Oxf) 2:281–287CrossRef
11.
Gatalica Z, Chen M, Snyder C (2014) Barrett’s esophagus in the patients with familial adenomatous polyposis. Fam Cancer 13:213–217CrossRef
12.
Gupta M, Dhavaleshwar D, Gupta V et al (2011) Barrett esophagus with progression to adenocarcinoma in multiple family members with attenuated familial polyposis. Gastroenterol Hepatol (NY) 7:340–342
13.
Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G: C → T: A mutations in colorectal tumors. Nat Genet 30:227–232CrossRef
14.
Ruggieri V, Pin E, Russo MT et al (2013) Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability. Oncogene 32:4500–4508CrossRef
15.
Vogt S, Jones N, Christian D et al (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985CrossRef
16.
Gallagher M, Phillips R, Bulow S (2006) Surveillance and management of upper gastrointestinal disease in Familial Adenomatous Polyposis. Fam Cancer 5:263–273CrossRef
17.
Katz PO, Gerson LB, Vela MF (2013) Diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 108:308–328CrossRef
18.
Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 103:788–797CrossRef
19.
Olyaee M, Sontag S, Salman W et al (1995) Mucosal reactive oxygen species production in oesophagitis and Barrett’s oesophagus. Gut 37:168–173CrossRef
20.
Jimenez P, Piazuelo E, Sanchez MT et al (2005) Free radicals and antioxidant systems in reflux esophagitis and Barrett’s esophagus. World J Gastroenterol 11:2697–2703CrossRef
21.
Hardikar S, Onstad L, Song X et al (2014) Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett’s esophagus cohort. Cancer Epidemiol Biomark Prev 23:2393–2403CrossRef
Metadata
Title
Increased prevalence of Barrett’s esophagus in patients with MUTYH-associated polyposis (MAP)
Authors
Ceranza G. Daans
Zeinab Ghorbanoghli
Mary E. Velthuizen
Hans F. A. Vasen
George J. A. Offerhaus
Miangela M. Lacle
Peter D. Siersema
Margreet G. E. M. Ausems
Jurjen J. Boonstra
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2020
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00162-9

Other articles of this Issue 2/2020

Familial Cancer 2/2020 Go to the issue

Original Article

Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway

Original Article

Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome (LS): a descriptive study

Original Article

Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer

Short Communication

De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer

Original Article

Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics

Original Article

The (ir)relevance of the abandoned criterion II for the diagnosis of serrated polyposis syndrome: a retrospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits